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ABSTRACT 
MYC is implicated in the development and progression of Pancreatic cancer, yet the precise level of 
MYC deregulation required to contribute to tumour development has been difficult to define.  We 
used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the 
pancreatic phenotypes arising in mice from an approximation of MYC trisomy.  We show that this 
level of MYC alone suffices to drive pancreatic neuroendocrine tumours, and to accelerate 
progression of KRAS-initiated precursor lesions to metastatic pancreatic ductal adenocarcinoma.  
Our phenotype exposed suppression of the Type I Interferon pathway by the combined actions of 
MYC and KRAS and we present evidence of repressive MYC/MIZ1 complexes binding directly to the 
promoters of type I Interferon regulators IRF5, IRF7, STAT1 and STAT2.  De-repression of Interferon 





We define herein a novel mechanism of evasion of NK cell-mediated immunity through the 
combined actions of endogenously expressed mutant KRAS and modestly deregulated expression 
of MYC, via suppression of the Type I Interferon pathway.  Restoration of Interferon signalling may 
improve outcomes for PDAC patients.  45 words  
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INTRODUCTION 
Cancers of the pancreas are projected to become the 2nd most frequent cause of cancer-related 
mortality worldwide by 2030 (1).  Ductal adenocarcinoma (PDAC) comprises up to 95% of pancreatic 
cancers, while neuroendocrine tumours (PNET) and other exocrine tumours account for remainder 
https://www.pancreaticcancer.org.uk/; https://seer.cancer.gov/statistics/. The 5-year survival rate 
for PDAC is extremely low at 3-5% and, although that for PNET is considerably higher (30-50%), 
neither cancer responds effectively to current treatment modalities (2). There is therefore a 
pressing need to further our understanding of the underlying biology of these cancers. 
 Activating mutations in KRAS occur in up to 93% of PDAC, while the majority of KRAS wild-
type cases bear alternative genetic alterations predicted to result in ectopic RAS->ERK pathway 
activity, implying a critical requirement for this pathway in PDAC (3, 4).  Experiments in genetically 
altered mice have however demonstrated that KRas activation is alone insufficient for PDAC 
development: CRE-dependent activation of the endogenously expressed lsl-KRasG12D allele (5) alone 
gives rise predominantly to low-grade pancreatic intraepithelial neoplasms (PanINs), a subset of 
which may spontaneously progress to PDAC through the acquisition of additional mutations (6-8). 
Recent genomic characterisation of cell lines generated from such spontaneously progressing 
tumours revealed increased K-RasG12D allelic dosage as one of the most frequently recurring genetic 
alterations associated with progression (9), suggesting that the volume of signalling flux through the 
RAS pathway is rate-limiting for PDAC progression, as was recently shown for KRAS-driven lung 
cancer (10-13).  Interestingly, cell lines that lacked increased KRasG12D allelic dosage contained 
amplifications of alternative oncogenes that may serve as potentially rate-limiting RAS effectors, 
including MYC, YAP1 and NFkB (9, 14).  MYC in particular is widely reported to be overexpressed in 
PDAC, with a propensity for low-level amplification suggesting that subtle changes in MYC 
expression may suffice to impact on PDAC development (15, 16).  Accordingly, expression of murine 
c-Myc from the Rosa26 locus was recently shown to accelerate progression to PDAC, however the 
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use of murine c-Myc cDNA in the transgene precluded a precise determination of the level of MYC 
deregulation required for tumour progression (17).  Conversely, deletion/depletion of endogenous 
c-Myc profoundly delayed progression of PDAC driven by KRasG12D and loss of p53 (18, 19), while 
RNAi-mediated depletion of c-MYC in human PDAC cells suppressed proliferation in vitro and 
xenograft tumourigenesis in vivo (20), consistent with the hypothesis that MYC is a critical rate-
limiting effector of KRAS in this cancer. 
 Here, we directly investigated the level of MYC deregulation required for pancreatic tumour 
development using conditional expression of human c-MYC from the Rosa26 locus at levels that 
approximate expression of endogenous c-Myc.  We show that modestly deregulated expression of 
MYC alone suffices to drive PNET development and dramatically accelerates progression to 
metastatic PDAC when combined with KRas activation.  In PDAC, the combination of MYC & KRasG12D 
suppresses tumour infiltration of effector immune populations, as recently reported (21).  
Mechanistically, we reveal that MYC and KRasG12D cooperatively regulate gene expression, with 
particular convergence on repression of the Type I Interferon pathway.  We show that targeted 
suppression of the MYC/Miz1 transcriptional repressor complex (22) restores interferon-related 
gene expression and consequent B and NK cell-mediated immune surveillance.  Our data reveal a 






Rosa26-driven MYC is expressed at near physiological levels 
In order to define the level of MYC deregulation required for pancreatic tumour development, we 
used Rosa26DM-lsl-MYC mice wherein the human c-MYC cDNA, preceded by a floxed translational stop 
cassette, was inserted into the murine Rosa26 locus by homologous recombination, as previously 
described (23).  Use of the human cDNA facilitated the distinction between endogenously expressed 
murine c-Myc and Rosa26-driven MYC.  RT-PCR demonstrated Cre-dependent expression of human 
MYC in Rosa26DM-lsl-MYC/+ and Rosa26DM-lsl-MYC/lsl-MYC-derived mouse embryo fibroblasts (MEFs) within 
24hrs of infection with Adeno-Cre.  Expression of one copy of human MYC mRNA was comparable 
to murine c-Myc, while 2 copies yielded modestly supraphysiological expression (Fig. 1A).  
Consistent with previous reports that MYC regulates its own transcription (24), Rosa26MYC/MYC MEFs 
exhibited reduced expression of endogenous c-Myc and were modestly sensitised to apoptosis upon 
serum withdrawal (Fig. 1B).  At the protein level, activation of Rosa26DM-lsl-MYC/+ drove modestly 
higher expression of MYC compared with wild-type (wt) MEFs.  Notably, Cre-dependent activation 
of endogenously expressed lsl-KRasG12D also drove higher expression of MYC protein, comparable 
to that arising from Rosa26MYC/+, and expression was higher again upon combined activation of both 
alleles (Fig. 1C). 
 
Deregulated MYC drives pancreatic tumour development and progression 
RAS pathway activity elevates MYC expression in pancreatic cancer, primarily via suppression of 
MYC protein turnover, and MYC was previously shown using RNAi to be required for proliferation 
of PDAC cells in culture (20, 25, 26).  Use of the PICKLES database of CRISPR-mediated essentiality 
screening (27) confirmed the requirement for MYC to sustain the fitness of all PDAC lines examined, 
including several lines that do not require KRAS (Fig. S1A).  We asked if MYC expressed from the 
Rosa26 locus is sufficient for tumour formation.  We interbred Rosa26DM-lsl-MYC mice (M) with 
	 7	
pancreas-specific Pdx1-Cre mice (C), with and without the lsl-KRasG12D allele (K), and aged mice until 
humane clinical end-points were reached.  Pdx1-Cre positive mice carrying one (MC) or two (M2C) 
copies of Rosa26DM-lsl-MYC developed pancreatic tumours requiring euthanasia at a median age of 
297 or 180 days, respectively.  The combination of lsl-KRasG12D and one copy of Rosa26DM-lsl-MYC 
(KMC) yielded a dramatically accelerated tumour phenotype requiring euthanasia at a median age 
of just 50 days, as compared with KC mice that have a median survival >350 days (Fig. 2A-C).  In 
contrast with KC mice, which developed mostly ductal epithelial PanIN lesions with infrequent 
progression to PDAC, as previously reported (6), MC and M2C pancreata showed no evidence of 
ductal epithelial phenotypes and instead presented with neuroendocrine tumours (PNET) 
characterised by densely populated cells that stained strongly for the neuroendocrine marker 
synaptophysin and faintly positive for cytokeratin (Fig. 2D & S1B).  This PNET phenotype was largely 
masked upon inclusion of the lsl-KRasG12D allele: rapidly arising tumours in KMC mice displayed a 
predominantly ductal adenocarcinoma phenotype (PDAC), complete with characteristic 
desmoplastic stroma, while <5% of tissue area exhibited PNET features (Fig. S1B, C).  PNET regions 
in KMC tumours expressed KRasG12D (Fig. S1D), indicating that the persistence of this phenotype 
does not arise from failure to activate the lsl-KRasG12D allele in a subset of pancreatic tumour-
initiating cells. 
 
Sporadic adult activation of Rosa26DM-lsl-MYC and lsl-KRasG12D drives metastatic cancer 
The Pdx1 promoter is active from embryonic day 8.5 (28), raising the possibility that blockade of 
pancreatic progenitor cell differentiation might explain the MYC-dependent neuroendocrine and 
accelerated PDAC phenotypes. To address this, we substituted the constitutively active Pdx1-Cre 
allele with a Pdx1-Cre-ER allele (CER) which expresses an inactive Cre:Estrogen Receptor ligand-
binding domain fusion protein that can be activated by the synthetic ligand Tamoxifen (29).  KMCER 
mice were additionally interbred with mice carrying a Hprt-lsl-IRFP Cre-reporter allele (30), to 
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facilitate imaging of tumour populations (Fig. 2E).  Cre-ER was transiently activated in mice aged 5-
6 weeks by 3 days of Tamoxifen injection, and mice were aged to clinical end-point.  As was found 
using the constitutively active Cre, all M2CER mice developed neuroendocrine tumours, reaching 
median end-point at 275 days from the date of induction, although the majority of MCER mice failed 
to develop symptomatic disease within 400 days.  KMCER mice all developed PDAC, reaching median 
end-point at 128 days post-induction (Fig. 2F).  Periodic sampling of KMCER pancreatic tissue 
following Cre-ER activation showed temporal progression of incipient tumours from PanIN-1 
through to PDAC development (Fig 2G).  Furthermore, the IRFP allele revealed metastases in 6/10 
mice, of which 4 had liver metastases while 4 had diaphragm metastases, including 2 mice with both 
(Fig. 2H).  As observed with KMC tumours, KMCER tumours contained regions (approx. 15% of 
tumour area) of PNET (Fig. S1C).  All liver metastases histologically resembled the PNET phenotype 
and all stained strongly for synaptophysin.  In contrast, diaphragm metastases all histologically 
resembled PDAC, but also contained discrete regions where cells stained strongly for either 
cytokeratin or synaptophysin, suggestive of phenotypic plasticity in the metastatic population (Fig. 
2H).  Accordingly, synaptophysin/cytokeratin double positive cells could be identified in the ductal 
epithelium of primary tumours (Fig. S1E), as previously reported using the embryonically active 
Pdx1-Cre allele (17).  The accelerated tumour phenotypes observed upon MYC deregulation can 
thus arise in fully developed adult tissues. 
  
Endogenous c-Myc is required for KMC tumour development 
Given the modest expression of Rosa26-driven MYC in MEFs, we asked if autochthonously 
expressed c-Myc contributes meaningfully to the total pool of MYC protein in the KMC model.  Note 
that while KRas activation does not impact upon transcription from the Rosa26 locus, which we 
previously showed is refractory to growth factor signalling (31), post-translation regulation of MYC 
protein by RAS pathway activation should affect murine and human MYC protein equally (32).  
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Accordingly, deletion of floxed murine c-Myc in MEFs reduced the total pool of MYC protein by 
approximately 50%, despite concurrent activation of Rosa26DM-lsl-MYC and lsl-KRasG12D alleles (Fig. 
3A).  KMC mice interbred with c-Mycfl/fl mice were aged until humane end-points were reached.  
KMC mice heterozygous for floxed c-Myc showed significantly increased survival and survival was 
increased further in homozygous c-Mycfl/fl mice (Fig. 3B, C).  Nevertheless, all mice developed PDAC.  
Examination of murine c-Myc by in situ hybridization (ISH) revealed a mosaic pattern of continued 
expression of murine c-Myc in much of the ductal epithelium of all KMC-Mycfl/fl tumours examined, 
indicating escape from Cre-mediated deletion and suggesting a selective pressure to retain 
expression of endogenous c-Myc despite the presence of Rosa26-driven MYC (Fig. S2A, B).  This MYC 
dose-dependence was also evident in human PDAC cell lines, wherein depletion of MYC suppressed 
cell proliferation (Fig. S2C), consistent with previous reports (20).  These data strongly suggest that 
the level of MYC expression is rate-limiting for pancreatic tumour progression and, in KMC mice, 
both Rosa26-driven MYC and endogenously expressed c-Myc functionally contribute to the total 
pool of MYC protein. 
 
MYC suppresses immune cell infiltration in PDAC 
To gain insight into the functional roles of MYC in PDAC, we performed bulk-tumour RNA-SEQ on 6 
KC, 6 KMC, and 4 KMC-Mycfl/+ end-stage tumours. Note that homozygous KMC-Mycfl/fl mice were 
omitted from RNA-SEQ analysis given that the failure of Cre recombinase to efficiently delete both 
copies of endogenous c-Myc would likely confound interpretation.  Metacore GeneGO analysis 
revealed a pronounced reduction in immune cell-related gene expression in KMC relative to KC 
tumours (Figure S3).  Specifically, we found reduced expression of T cell markers, including CD3, CD4 
& CD8 (Fig. S4A); B cell immunoglobulin genes, including multiple constant heavy and light chains 
along with joining regions; and NK cell genes, including Natural Killer Triggering Receptor, Nktr, and 
Killer-type lectin receptors (Fig. 3D, E).  IHC for markers of B (CD45R) and NK (NKp46) cells confirmed 
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their reduced presence in KMC PDAC (Fig. 3F, G).  Reduction of total MYC by deletion of endogenous 
c-Myc reversed the exclusion of B and NK cells but did not significantly influence T cell infiltration 
(Fig. 3F, G & S4B, C).  RNA-SEQ analysis showed increased expression of multiple killer-type lectin 
receptors, indicative of NK cell activation and memory (33), upon reduction of MYC in KMC tumours 
(Fig. 3H).  Taken together with Figures 1 & 2,  these data show that subtle differences in MYC 
expression profoundly modulates long-term immune cell infiltration in PDAC, extending a recent 
report of acute immune modulation by MYC using a tamoxifen-dependent variant allele, Rosa26-lsl-
MycERT2 (21). 
 
Suppression of the Type I Interferon pathway by MYC and KRAS 
MYC was previously shown to modulate the immune landscape in KRAS-driven lung 
adenocarcinoma via Ccl9-dependent recruitment of pro-tumour macrophages and Il23-dependent 
exclusion of T, B & NK cells (34).  Expression of Ccl9 was not significantly altered in our RNA-SEQ 
datasets and we found no difference in the number of macrophages present in end-stage KMC 
versus KMC-Mycfl/fl tumours (Fig. S4D, E).  Functional IL23 comprises a heterodimer of p19 and p40 
subunits, encoded by IL23a and IL12b, respectively (35).  Although Il23a expression was higher in 
KMC versus KC tumours and significantly reduced in KMC-Mycfl/+ tumours, its dimerizing partner 
Il12b showed opposite regulation (Fig. S4F), strongly suggesting that Il23 does not account for the 
immunosuppressive phenotype driven by MYC in PDAC.  Expression of Gas6, recently reported to 
be induced upon acute MYC activation in PanIN lesions (21), was unchanged in end-stage tumours 
(Fig. S4G).  We therefore sought an alternative explanation for MYC-driven immunosuppression.  
Type I Interferon signalling via JAK/STAT was amongst the most strongly suppressed 
pathways (ranked 6th) in KMC relative to KC tumours (Fig. S3).  Taking advantage of our ability to 
acutely induce expression of floxed MYC and KRasG12D in otherwise wild-type primary cells, we asked 
which pathways were regulated upon acute activation of MYC and/or KRas in MEFs.  Early passage 
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MEFs carrying Rosa26-lsl-MYCDM, lsl-KRasG12D, or both, were infected with Adeno-CRE overnight in 
full growth media and their gene expression was compared with that of similarly infected wild-type 
littermate MEFs.  Consistent with positive regulation of MYC by activated KRas (Fig. 1), we found a 
pronounced overlap in the transcriptomic impact of activation of either oncogene alone (Fig. S5A-C 
& Table S1-S3).  Similar to our comparison between KMC and KC tumours, GeneGO analysis 
identified Type I Interferon signalling via JAK/STAT as the most significantly downregulated pathway 
upon combined activation of MYC and KRas alleles (Fig. S5D).  Interrogation of the data at the single 
gene level showed reduced expression of multiple Interferon-induced genes; multiple Interferon 
Regulatory Factors; and genes encoding STAT1 and STAT2, which combine with IRF9 to form the 
ISGF3 complex (36).  Although several of these effects were evident with activation of either MYC 
or KRasG12D alone, regulation was most pronounced upon combined oncogene activation (Fig. 4A, 
S5D).  
We next compared the transcriptomic impact of acute depletion of MYC or KRas from KMC-
derived tumour cell lines.  As was observed in MEFs, we found a pronounced overlap in significantly 
regulated genes altered in murine PDAC cells upon depletion of either MYC or KRas (Fig. 4B & S5E).  
Notably, the Type I interferon pathway was again amongst the topmost regulated pathways in both 
instances (Fig. S5F), with increased expression of the ISGF3 complex subunits, multiple Irfs, 
Interferon receptors, and Interferon-induced genes, detected upon depletion of either oncogene. 
These effects were typically stronger upon KRas depletion and some Irf genes (eg. Irf5) were 
regulated by KRas but not by MYC in this analysis, perhaps reflecting the limits of transcript 
detection at the sequencing read-depth used (Fig. 4C).  To extend these data to the human setting, 
we treated PDAC cell lines with the MEK1/2 inhibitor Trametinib, which acutely reduced expression 
of c-MYC downstream of KRAS (Fig. 4D).  In both AsPC-1 and DAN-G cells Trametinib increased 
expression of IRF5, IRF7, IFNb1 and a representative Interferon-inducible gene, IFI44 (Fig. 4E).  We 
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conclude from these experiments that MYC and KRAS cooperate to suppress the Type I Interferon 
pathway. 
 
The role of MIZ1 in suppression of Interferon regulators by MYC 
In many instances MYC-dependent transcriptional repression involves binding to the MYC-
interacting zinc finger protein MIZ1, encoded by ZBTB17 (18, 37).  We therefore investigated the 
acute impact of Miz1 depletion in KMC PDAC cells in vitro.  Transcriptomic analysis revealed that 
depletion of Miz1 upregulated approximately 60% of the same genes upregulated upon depletion 
of MYC from KMC cells (Fig. 5A & Table S4).  Using Q-PCR we determined that depletion of Miz1 or 
MYC specifically increased expression of Irf5, Irf7, Ifnb1 and Ifi44 (Figs. 5B, S6A), as was found upon 
Trametinib treatment of human PDAC cells.  Chromatin immunoprecipitation (ChIP) analyses 
showed MYC binding to the promoters of STAT1, STAT2, IRF5 and IRF7 in DAN-G cells (Fig. 5C).  ChIP-
re-ChIP using an anti-MIZ1 antibody showed efficient recovery of the same IRF & STAT promoter 
fragments initially precipitated using anti-MYC but absent from control IgG precipitates, strongly 
suggesting that MYC and MIZ1 form repressive complexes on the STAT1, STAT2, IRF5 and IRF7 
promoters (Fig. 5D & S6B), as previously reported for the Stat1 promoter in murine KPC PDAC cells 
(18).  To investigate the functional role of Miz1 in vivo we used Miz1DPOZ mice (38) in which the MYC-
interacting POZ domain of Miz1 is flanked by LoxP sites (Fig. 5E).  Efficient deletion of the Miz1 POZ 
domain in KMC-Miz1fl/fl mice was verified by ISH & significantly extended the lifespan of tumour-
bearing mice (Figs. 5F & S6C).  PDAC subtype analysis performed as per Bailey et al. (3) revealed that 
deletion of either c-Myc or Miz1 significantly increased the immunogenic subtype signature but did 
not significantly alter any of the other subtypes (Fig. S6D).  As was observed upon deletion of 
endogenous c-Myc, deletion of Miz1 restored tumour infiltration of NK and B cells (Fig. 5G).  
Antibody-mediated blockade of the Type I Interferon receptor, IFNAR, suppressed NK and B cell 
infiltration and negated the survival benefit of Miz1 deletion in tumour-bearing KMC mice (Fig. 5H-
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J), implicating Interferon signalling in lymphocyte recruitment and in the survival benefit observed 
upon Miz1 deletion. 
 
Interferon signalling to NK and B cells is mediated by CXCL13 
Type I Interferons were recently shown to induce expression of the B cell chemokine, CXCL13 (39).  
RNA-SEQ analysis showed extremely high expression of Cxcl13 in KMC-Miz1fl/fl tumours, as 
compared with KMC tumours that express very little Cxcl13 (Fig. 6A).  ISH analysis of KMC-Miz1fl/fl 
tumours showed Cxcl13 expression was restricted to a subset of F4/80-positive macrophages (Fig. 
6B).  Notably, only macrophages in close proximity to areas of ductal tumour epithelium stained 
positive for Ccxl13 mRNA, suggesting paracrine signalling from tumour epithelium to adjacent 
macrophages.  A similar, albeit weaker, pattern of Cxcl13 expression in F4/80-positive macrophages 
adjacent to ductal epithelium was observed in KMC-Mycfl/fl tumours but was absent from KMC 
tumours (Figs. 6A, S6E).  We used exogenous mouse IFNb1 treatment of bone marrow-derived 
macrophages to confirm that Interferon can stimulate Cxcl13 expression in macrophages (Fig. 6C).  
Next, we cultured macrophages with conditioned media harvested from KMC tumour cells treated 
with non-targeting or MYC-depleting siRNA and found that only media from MYC-depleted tumour 
cells could stimulate Cxcl13 expression. Importantly, pre-treatment of macrophages with IFNAR1 
blocking antibody completely abrogated Cxcl13 induction (Fig. 6D), confirming that Type I Interferon 
released from MYC-depleted tumour cells drives Cxcl13 production in macrophages. Antibody-
mediated depletion of Cxcl13 from KMC-Miz1fl/fl mice suppressed infiltration of both B and NK cells 
and negated the survival benefit of Miz1 deletion (Fig. 6E-G), whereas isotype control antibody had 
no effect (Fig. S6F).  Depletion of NK cells likewise negated the survival benefit, strongly suggesting 
that they actively restrain the tumour phenotype (Fig. 6H, S6G).  Accordingly, co-culture of KMC 
tumour cells with in vitro-activated splenocytes enriched for NK cells showed that KMC tumour cells 
are efficiently killed by NK cells, equivalent to the established NK target cell line, YAC1 (40), in 
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contrast with primary fibroblasts that are largely resistant to NK-mediated killing (Fig. 6I).  Taken 
together, these data delineate a pathway by which KRAS and MYC cooperate to evade NK-mediated 




The evasion of anti-tumour immunity has emerged in recent years as a major hallmark of cancer 
that presents genuine therapeutic opportunities through the targeted suppression of immune-
evasion mechanisms, often with long-term patient benefit.  Most efforts to date have focussed on 
mechanistic evasion of T lymphocyte-mediated tumour immunity, with targeted blockade of CTLA4 
and PD1/PD-L1 establishing a paradigm for successful therapeutic exploitation of immuno-
oncology.  Here we present evidence of a novel mechanism of evasion of innate tumour immunity 
achieved through cooperation of the frequently dysregulated oncogenes MYC and KRAS via 
suppression of the Type I Interferon pathway. 
 We identified the Type I Interferon pathway as a major target of oncogene-mediated 
suppression through the unbiased analysis of multiple RNA-SEQ datasets: comparing end-stage 
pancreatic tumours driven by KRasG12D alone with those driven by the combination of KRasG12D & 
MYC; comparing KMC-derived tumour cells depleted of MYC, Miz1 or KRas with mock-depleted 
parental cells; comparing MEFs upon acute activation of lsl-KRasG12D, Rosa26DM-lsl-MYC, or both, with 
wild-type littermate controls.  In all such comparisons the Type I Interferon pathway ranked 
amongst the pathways most significantly regulated.  Although our mechanistic analysis here was 
performed exclusively in the context of pancreatic cancer, the conservation of this regulation in 
MEFs suggests that suppression of Type I Interferons may be a general feature of cancers wherein 
MYC and KRAS are dysregulated.  For instance, a strong negative correlation between tumours with 
an IRF8/9 gene signature and those with a MAX gene signature (MAX being the obligate 
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heterodimerising partner of MYC) was recently reported in Mesothelioma (41).  Moreover, the Type 
I Interferon gene cluster is syntenic with CDKN2A/B on Chromosome 9 and is frequently co-deleted 
with the latter in a spectrum of human cancers: Across multiple cancers, patients with co-deletion 
show significantly reduced overall survival compared with those that retain the Interferon gene 
cluster, providing further evidence of an anti-tumour role for this pathway and a selective pressure 
for cancers to reduce its activity (42). 
 Mechanistically we present evidence of repressive MYC/Miz1 complexes binding to the 
promoters of STAT1, STAT2, IRF5 and IRF7.  These data are complemented by a previous report of 
MYC/Miz1 binding to the Stat1 promoter in KPC (KRasG12D;Tp53R172H) murine pancreatic tumour cells 
(18) and MYC repression of STAT2 in breast cancer cells (43).  Recent work has shown that basal 
expression of many Interferon-stimulated genes is regulated by STAT2/IRF9 complexes 
independently of IFNAR signalling.  Upon Interferon-dependent activation of IFNAR, signalling 
through JAK family kinases leads to STAT1 binding to STAT2/IRF9 to form the ISGF3 complex (36), 
driving expression of, amongst other genes, IRF7, which in turn is strictly required for 
IFNa/b production (44).  Note that other STAT family members may have very different effects, as 
recently evidenced by STAT6 driving expression of c-Myc during PDAC progression in response to 
Th2-derived interleukins (45).  MYC/Miz1 thus attenuates the Type I Interferon cascade at multiple 
points that would limit both basal and Interferon-stimulated gene expression.  The effects of KRAS 
on this pathway appear to be largely a consequence of MYC stabilisation, at least in PDAC cells (25), 
however, signalling cross-talk between the RAS and JAK-STAT pathways likely contributes to some 
of the MYC-independent effects observed, or indeed to the stronger effects of KRAS modulation in 
these systems (46).  Similarly, Miz1 likely has additional roles in PDAC beyond its function as a MYC-
corepressor, evidenced by divergent regulation of some 40% of MYC-regulated genes upon acute 
depletion of Miz1 in KMC cells.  The fact that Miz1 could be efficiently deleted in ductal tumour 
epithelium, unlike endogenous Myc, argues that its role in PDAC is more limited and likely explains 
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the stronger impact of the floxed Miz1 genotype upon Cxcl13 induction in vivo, as compared with 
the floxed c-Myc allele. 
 We demonstrate that de-repression of the Type I Interferon pathway in PDAC tumour cells 
stimulates production in nearby macrophages of the canonical B cell chemokine Cxcl13, resulting in 
tumour infiltration of B and NK cells.  Although the recruitment of NK cells may well be an indirect 
consequence of B cell recruitment, as suggested by recent data (21), evidence is emerging of a direct 
role for CXCL13 in NK cell recruitment and a subset of NK cells express the CXCL13 receptor, CXCR5 
(47).  Depletion of Cxcl13 or blockade of the Type I Interferon receptor, IFNAR, each suppressed B 
and NK cell infiltration and reversed the survival benefit of Miz1 deletion in KMC tumours.  Using 
co-culture experiments we showed that NK cells can efficiently kill KMC tumour cells, and that their 
depletion also negated the survival benefit observed upon Miz1 deletion.  As is the case with 
cytotoxic T cells, NK cells express a variety of activating and repressing surface markers that are 
amenable to extrinsic modulation. As such, targeted activation of NK cells is emerging as an 
attractive therapeutic option, particularly in tumours with low mutation burden or lack of PD-L1 
expression (48). 
 It would be implausible to suggest that the dramatic acceleration of PDAC development 
observed upon MYC and KRasG12D co-expression is entirely explained by these effects on the 
immune landscape.  Indeed, these are highly pleiotropic oncogenes with broad influence over many 
cell-intrinsic and cell-extrinsic biological features (21, 45).  It is notable however that regulation of 
the Type I Interferon pathway occurs upon physiological expression of KRasG12D or upon very modest 
overexpression of c-MYC, suggesting that this regulation may be present from the very outset of 
tumour initiation.  This raises the exciting possibility of early intervention to reactivate Interferon 
signalling.  Although we show that pharmacological inhibition of the RAS pathway can restore 
Interferon related gene expression in vitro, we would caution against such an approach in vivo given 
that immune cells use the very same RAS pathway to achieve their own rapid expansion (49).  What 
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is clear however is that a very modest increase in MYC suffices to dramatically accelerate KRAS-
initiated tumours to metastatic PDAC, as we previously reported for lung adenocarcinoma (12), or 







All experiments involving mice were approved by the local animal welfare (AWERB) committee and 
conducted under UK Home Office licences, PE47BC0BF, 70/7950 and 70/8375.  Mice were 
maintained on a constant 12hr light/dark cycle, fed and watered ad libitum, and all were mixed 
background (FVBN and C57Bl/6).  The following genetically modified mice were described 
previously: Lsl-KRasG12D (5); Rosa26DM-lsl-MYC (23); Pdx1-Cre (6); Pdx1-CreER (29); c-MycFl (50); Hprt-
lsl-IRFP (30); Miz1DPOZ (38).  All genotyping was performed by Transnetyx Inc.. To induce allele 
recombination, CreERT2 was activated in the pancreas of 5-6-week old mice by IP injection of 2mg/kg 
Tamoxifen (dissolved in peanut oil) for 3 consecutive days.  For overall survival analysis, cohorts of 
mice were monitored and euthanized when clinical end-point was reached. Endpoint monitoring 
was performed by facility staff without knowledge of genotype.  For histological analysis, mouse 
tissues were fixed with 10% neutral buffered formalin overnight.  At euthanasia, a small portion of 
pancreatic tumour was snap frozen for RNA analysis.  To determine the influence of Cxcl13, a cohort 
of randomly selected KMC-Miz1DPOZ mice were treated with Cxcl13 blocking antibody (0.5µg, IV, 
AF470, R&D Systems) or isotype control (Goat IgG, AB-108-C R&D) from 6 weeks of age, twice 
weekly for 3 weeks, and sacrificed at clinical end-point.  To determine the influence of IFN signalling, 
a cohort of randomly selected KMC-Miz1DPOZ mice were treated with IFNAR1 blocking antibody 
(clone MAR1.5A3, BE0241, BioxCell) IP, 200µg/20g body mass on first dose and 100 µg/20g for the 
following 6 doses, from 6 weeks of age, once every 3 days for 3 weeks, and sacrificed at clinical 
endpoint.  For NK cell depletion, 6 week old mice were treated with anti-NK1.1 (clone PK136, 
BP0036, BioxCell), IP, 100ug/20g, 2 doses in the first week and once per week for the following 3 
weeks.  To verify NK cell depletion following the NK1.1 antibody treatment, blood was sampled by 
tail bleed from mice prior to and after 2 weeks treatment.  Cells were stained with CD45 (10311, 
Biolegend), CD3 (100327, Biolegend), NK1.1 (108707, Biolegend), NkP46 (137612, Biolegend) & 
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Zombie NIR10311, (423106, Biolegend) after RBC lysis (eBioscience, 00-4333-57) and analysed by 
flow cytometry (BD Fortessa). FACS profiles were generated and quantified using FlowJo (Tree Star). 
Rosa26DM-lsl-MYC mice are available from Jaxmice at https://www.jax.org/strain/033805. 
 
Immunohistochemistry and Tissue Analysis  
All immunohistochemistry and in situ hybridization staining were performed on 4 µm formalin fixed 
paraffin embedded sections which had previously been heated to 60⁰C for 2 hours.  Peroxidase 
blocking was performed for 10 mins in 1% H2O2 diluted in H2O, followed by heat mediated or enzyme 
mediated antigen retrieval. Non-specific antibody binding was blocked with up to 3% BSA or up to 
5% normal goat serum for 1h at RT. The following antibodies were used at the indicated dilution 
and indicated antigen retrieval method: Synaptophysin (ab8049, 1:50, pH6), CD45R (ab64100, 
1:200, ER2 Leica), NKp46 (aF2225, 1:200, pH6), F4/80 (ab6640, 1:100, Enzyme 1 Leica), MYC 
(ab32072, 1:100, pH6)[Abcam], KRasG12D (CST14429, 1:50, pH9)[Cell Signaling Tech.], pan-
Cytokeratin (MS-343, 1:100, pH6)[ThermoFisher].  Nkp46, Pan-cytokeratin and Synaptophysin were 
stained on a Dako AutostainerLink48, CD45R and F4/80 were stained on the Leica Bond Rx 
autostainer; KRasG12D and MYC were stained manually.  Mouse EnVision (Agilent), Goat ImmPRESS 
Kit and Rabbit (Vector Labs) were used as secondary antibodies.  The HRP signal was detected using 
liquid DAB (Agilent and Invitrogen).  Sections were counterstained with haematoxylin and cover-
slipped using DPX mount (Cellpath, UK).  In situ-hybridisation detection for Cxcl13 (ACD 406318), 
Miz1 (ACD 520288) and PP1b (ACD 313918; Advanced Cell Diagnostic, Hayward, CA) mRNA was 
performed using RNAscope 2.5 LS detection kit (ACD).  Detection of murine c-Myc (ACD 712368) 
was performed using a BaseScope 2.5 LS detection kit (ACD).  Both techniques were performed on 
a Leica Bond Rx autostainer, strictly adhering to ACD protocols.  Tumour area was calculated using 
HaLo software (Indica Labs) as the percent area of pancreas occupied by ductal adenocarcinoma 
(PDAC) and neuroendocrine tumours (PNET), measured on haematoxylin & eosin (H&E) stained 
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sections. To quantify the immune infiltration, positive cells were counted manually using QuPath 
cell (https://qupath.github.io/) counter function and normalized to tumour area (PDAC+PNET) 
calculated as described above. 
 
Cell culture 
Human pancreatic cell lines were obtained from ATCC and were maintained in DMEM (MIA PaCa-2) 
or RPMI (AsPC-1, DAN-G) supplemented with 10% FBS and Pen/Strep.  All cell lines were validated 
using an approved in-house validation service (CRUK-BICR) and tested periodically for mycoplasma. 
Cell lines were thawed from primary stocks maintained under liquid nitrogen & cultured for a 
maximum of 8 weeks (< 20 passages), during which time all experiments were performed.  Cells 
were treated with 10nM (DAN-G) or 50nM (AsPC-1) Trametinib (MedChem Express) for 16hrs and 
used for protein and RNA analysis.  Primary mouse embryonic fibroblasts (MEFs) were generated 
from E13.5 embryos by interbreeding mice carrying Rosa26DM-lsl-MYC, lsl-KRasG12D and c-Mycfl/fl to 
obtain desired genotypes.  MEFs were cultured in DMEM with 10% FBS & Pen/Strep in 3% oxygen.  
To activate floxed alleles, MEFs were infected with 300 pfu/cell of Adeno-Cre (University of Iowa, 
vector core facility) and harvested at 24hrs.  Mouse pancreatic tumour lines were generated from 
end-stage KMC mice.  Tumours were disintegrated mechanically and cultured in DMEM 
supplemented with 20% FBS and Pen/Strep.  Once established, KMC cells were maintained in DMEM 
supplemented with 10% FBS and Pen/Strep.  For cell death measurements, cells were trypsinized, 
quenched with 1% BSA followed by replacement of original supernatant, and centrifuged at 300 x 
G for 5mins; 200µl of Annexin binding buffer (10mM HEPES pH 7.40, 140mM NaCl, 2.5mM CaCl2) 
and 2µl of Annexin V-APC (Biolegend 640920) were added to the pellet and incubated for 15mins.  
Propidium iodide (PI, 10µg/ml) was added immediately prior to FACS analysis.  For immunoblotting, 
whole cell lysates were prepared in RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 1% NP-40, 0.5% 
Sodium Deoxycholic acid, 1% SDS, plus complete protease and phosphatase inhibitor cocktail) 
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followed by sonication (40% Amp for 5s).  MYC (ab32072), Vinculin (ab129002), Histone H2B 
(ab1790) [Abcam], pERK1/2 (CST 4370), tERK1/2 (CST 4695) [Cell Signaling Tech.], Actin (SC 47778) 
[Santa Cruz], were used as primary antibodies. Secondary horseradish peroxidase-conjugated 
antibodies (a-mouse IgG NA931V; a-rabbit NA934V, both GE Healthcare; a -goat IgG, Vector Labs 
PI-9500) were detected by chemiluminescence (Biorad western blotting substrate 1705060).  To 
deplete MYC in human pancreatic cell lines, following siRNA were used: SiMYC 5 (Qiagen 
SI00300902), SiMYC 9 (SI03101847). To deplete MYC in mouse pancreatic tumour lines, a 
combination of mouse and human siRNA were used as follows: Pool 1 (SI01321012, SI00300902), 
Pool 2 (SI01321012, SI03101847), Pool 3 (SI01320991, SI00300902) (all fromQiagen).  To deplete 
Miz1 in mouse lines SI01320991 (Qiagen) was used.  To deplete KRas in mouse lines, SI02742439 
(Qiagen) was used.  
 
Bone marrow derived macrophages (BMDM) 
Bone marrow cells were isolated from wildtype mice by snipping the end of the femur and 
centrifuging at 5000 rpm for 1min.  Monocytes were differentiated into macrophages by culturing 
in non-TC treated plates (Corning, 430597) for 6 days in RPMI medium containing M-CSF (10ng/ml). 
Media containing M-CSF were replaced after 3 days.  Where indicated, BMDM’s were treated with 
recombinant mouse IFN-beta1 (8234-MB, R&D systems) for 4hrs (10ng/ml).  KMC tumour cells were 
used to generate conditioned media. Fresh media (DMEM+20%FBS) were added 24hrs after 
transfection with siMYC or non-targeting control siRNA.  24hrs later, conditioned media from MYC 
or non-targeting control depleted cells were collected, centrifuged (1200 rpm, 5mins), 
supplemented with M-CSF and, where indicated, anti-IFNAR1 blocking antibody (20ng/ml, BE0241, 
BioxCell) or mIgG (BE0083) prior to BMDM treatment.  BMDMs were additionally pre-treated with 
anti-IFNAR1 or mIgG overnight.  BMDM’s were treated with conditioned media for 24hrs.  To detect 
Cxcl13 expression in BMDM’s, cDNA was synthesized with Oligo-dT primer (M510, PromegA), pre-
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amplified (40nM of each primers, SYBR Green buffer, 1mg/ml BSA, 2.5% glycerol) for GusB and 
Cxcl13 for 20cycles. Diluted cDNA (1:20 in 10mMTris and 1mM EDTA) was quantified by real time 
PCR using SYBR Green method (VWR QUNT95072). 
 
In vitro cytotoxicity assay 
NK cells were activated ex vivo as previously described (51): Freshly isolated splenocytes of naïve 
mice at 3x106 cells/mL were treated for 72h with 50 ng/mL of IL-2 (Biolegend, Catalog # 575404).  
Target cells, stained with a cell trace dye (Thermofisher, Catalog # C34567 or V12883) following 
manufacturer instructions, were co-culture with different ratios (0, 5 and 10) of IL-2 stimulated 
splenocytes, enriched for activated NK cells.  After 4h co-incubation, cells were harvested, stained 
with Zombie NIR (Biolegend, Catalog # 423106) and analyzed by flow cytometry (BD Fortessa).  
FlowJo (Tree Star) software was used for analysis. 
 
Chromatin Immunoprecipitation  
Dan-G cells were cross-linked with formaldehyde (1% final conc.) for 10 min at 37oC.  Cells were 
scraped in PBS containing protease inhibitors and centrifuged at 300 x G for 5 min (4oC).  Cells were 
resuspended in lysis buffer 1 (5mM PIPES pH8, 85mM KCl, 0.5% NP40) and incubated on ice for 20 
min.  After lysis, cells were centrifuged at 300 x G for 5 min (4oC) and the pellets were resuspended 
in lysis buffer II (RIPA).  After 10 min incubation, lysates were sonicated to fragment DNA. Chromatin 
was precleared and IP’ed with 5µg of Myc (N262, SC764) or Miz1(B10, SC136985) antibody 
overnight at 4oC followed by incubation with 60µl of Protein G beads (17-0618-01, GE).  Rabbit IgG 
(CS2729) or Mouse IgG (BE0083) was used as antibody controls.  DNA was then eluted using elution 
buffer (1%SDS, 0.1M NaHCO3), de-crosslinked and purified using Qiagen PCR purification kit for Q-
PCR analysis.  For Re-CHIP, a-MYC or RIgG control IP’ed chromatin was eluted with Re-CHIP elution 
buffer (1xTE, 2%SDS, 15mM DTT) at 37oC for 30mins, IP’ed with 5 µg of Miz1 (B10, Sc136985) 
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antibody overnight at 4oC. The immunoprecipitated DNA was eluted as described above. The 
following primers sets were used: IRF7 promoter: gacaccagcctgaccaacatag, acaatcttggcccaccacaac; 
IRF5 promoter: aagagcaagagttaccaagcga, taaagaacctcaccccagaacc; IRF5 intronic region: 
ctctggctttctcctgcagacc, cccattgaagccctgggtact; STAT1 promoter: gctggtcgtcactctcacaa, 
tcgcctactcttaaggggct; STAT2 promoter: tccaggctcctcaagctagt, gcactttctacgaggggagg; VAMP4 
promoter: cagtggttgttcctcccta, ccgagccctattcacctaaa. 
 
RNA-SEQ Analysis 
Ribosome-depleted total RNA was used for analysis of mouse embryo fibroblast gene expression.  
Poly-A enriched RNA was analysed for bulk tumour and KMC cell line gene expression.  Datasets are 
available from ArrayExpress under accession numbers E-MTAB 6824 (MEFs); E-MTAB 8792 (KMC 
cell lines) and E-MTAB 8797 (PDAC tumours).  Full details of NGS protocols and downstream analysis 
are provided in the Supplementary Materials.   
 
Statistical analysis: 
Raw data obtained from quantitative Real Time PCR, FACS, & growth curves were copied into Excel 
(Microsoft) or Graphpad prism spreadsheets.  All Mean and SEM values of biological replicates were 
calculated using the calculator function. Graphical representation of such data was produced in 
Excel or Graphpad Prism.  Statistical significance was determined by the Student’s T test.  For 
multiple comparisons, ANOVA was used with a post-hoc Turkey test or post-hoc Fischer LSD test.  
For non-normally distributed data (eg. survival benefit; immune cell infiltration), Mantel-Cox (2-way 
comparison) or Kruskal-Wallis (multiple comparison) tests were performed.  For RNA-SEQ data, 
Adjusted P values calculated in R are shown. * denotes P<0.05; ** denotes P<0.01; *** denotes 
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Figure 1: Rosa26-driven MYC is expressed at near physiological levels 
A) RT-PCR comparison of Rosa26-driven MYC with endogenously expressed c-Myc in Rosa26wt/wt, 
Rosa26DM-lsl-MYC/+ and Rosa26DM-lsl-MYC/lsl-MYC MEFs, 24hrs after infection with Adeno-Cre.  N=3, * 
denotes p<0.05; ANOVA and post-hoc Tukey test.  ND = not detected.  B) FACS analysis of Annexin 
V (AV), propidium iodide (PI) labelling of MEFs, infected as per (A) with Adeno-Cre or Adeno-LacZ 
and cultured overnight in 0.2% FBS.  N=3, ** denotes p<0.01; ANOVA with post-hoc Tukey test.  C) 
Immunoblot of MYC expression in wild-type, Rosa26DM-lsl-MYC/+, lsl-KRasG12D and Rosa26DM-lsl-MYC/+;lsl-




Figure 2: Pancreatic cancer phenotypes induced by activation of Rosa26-driven MYC with  
 
and without KRasG12D 
 
A) Schematic of alleles used in panels B-D.  B) Overall survival of MC (N=9) and M2C (N=11) mice.  
Mantel Cox logrank test (panels B, C, F).  C) Overall survival of KC (N=65) versus MC (from (B)) and 
KMC (N=19) mice. Black hash marks indicate mice that were euthanised for reasons unrelated to 
pancreatic cancer. D) Representative images show tumour histology (H&E) and 
immunohistochemical detection of total MYC and KRasG12D expression in end-stage tumours of mice 
of the indicated genotypes.  Scale bar = 100µm.  E) Schematic of alleles used in panels F-H.  F) Overall 
survival of MCER (N=5), M2CER (N=6) and KMCER (N=10) mice measured in days post induction with 
Tamoxifen.  G) Representative H&E images of ductal tumour progression in KMCER mice.  Scale bars 
= 100µm.  H) Top panels show Licor PEARL fluorescent imaging of IRFP-expressing metastases in 
KMCER mice. Left panels show liver metastases, right panels show diaphragm metastases. Lower 
panels show H&E and IHC for pan-cytokeratin and synaptophysin.  Scale Bars = 100µm.   
	 32	
	
Figure 3: MYC expression levels modulate effector immune cell infiltration in PDAC 
A) Genetic deletion of endogenous c-Myc in Rosa26DM-lsl-MYC;lsl-KRasG12D MEFs.  Lysates were 
prepared 24hrs after Adeno-Cre infection.  Representative of 2 independent experiments.  B) 
Schematic of alleles used in panels C-G.  C) Overall survival of KMC mice with 0 (N=19, from Fig. 2C), 
1 (N=13) or 2 (N=8) copies of c-Mycfl. Mantel Cox Logrank test.  D) Normalised RNA-SEQ reads of 
indicated B cell markers in KC (N=6) and KMC (N=6) pancreatic tumours. Note that samples with 
zero reads are absent from log-scale graphics (pertains only to KMC samples).  Adjusted P values 
were generated in R (panels D, E, H).  E) Normalised RNA-SEQ reads of indicated NK cell markers in 
KC (N=6) and KMC (N=6) pancreatic tumours.  F) Quantification of tumour infiltrating NK (NKp46+) 
and B (CD45R+) cells in KC (N=7), KMC (N=10) and KMC-cMycfl/fl (N=9 & 12, respectively) pancreatic 
tumours.  Kruskal-Wallis and Dunn’s multiple comparison test.  G)  Representative images of IHC 
staining for NKp46+ NK cells (upper panels) and CD45R+ B cells (lower panels), as per (F).  Scale bars 
= 100µm.    H) RNA-SEQ reads of NK cell killer-type lectins in KMC (N=6) versus KMC-Mycfl/+ (N=4) 




Figure 4: MYC and KRasG12D suppress the Type I Interferon pathway 
 
A) RNA-SEQ analysis, of indicated gene expression in Rosa26wt/wt (WT), Rosa26DM-lsl-MYC/+(MYC), lsl-
KRasG12D (KRAS) and Rosa26DM-lsl-MYC/+;lsl-KRasG12D (MYC & KRAS) MEFs, 24hrs after infection with 
Adeno-Cre.  Adjusted P values were generated in R (panels A, C).  B) Heatmap of significant gene 
expression changes induced by depletion of MYC and KRas in KMC-derived cultured PDAC cells 
compared to non-targeting control, analysed by RNA-SEQ. N=4 biological replicates.  C) RNA-SEQ 
analysis of the indicated genes upon depletion of MYC or KRas in KMC PDAC cells, as per (B).  D) 
Reduced expression of MYC in human PDAC cells treated with Trametinib (T), compared with DMSO 
	 33	
vehicle (D).  Representative of 3 individual experiments.  E) RT-PCR analysis of Interferon-related 
gene expression in human PDAC cell lines treated +/- Trametinib.  Mean and SEM shown for N=3 
biological replicates.  For all panels, *** denotes p<0.001, **denotes p<0.01, * denotes p<0.05, ns 
= not significant. 
	
Figure 5: Transcriptional repression of the Type I Interferon pathway by MYC/Miz1 
A) Heatmap of gene expression changes induced by RNAi-mediated depletion of MYC or Miz1 in 
KMC-derived cultured PDAC cells compared to non-targeting (NT) control, analysed by RNA-SEQ.  
N=4 biological replicates.  B) RT-PCR analysis of Interferon-related gene expression in KMC tumour 
cells upon siRNA mediated depletion of Miz1 compared to non-targeting control.  Mean & SEM of 
3 independent experiments shown. T test.  C) Chromatin-IP analysis of MYC and Miz1 binding to the 
promoters of the indicated genes in human DAN-G PDAC cells compared with a known MYC/Miz1 
target, VAMP4.  Mean and SEM of technical replicates from 1 of 3 independent experiments shown. 
ANOVA and Tukey’s multiple comparison test.  D) Re-CHIP analysis of Miz1 binding to anti-MYC-
precipitated promoter regions.  Mean and SEM of technical replicates from 1 of 3 independent 
experiments shown.  T test.  E) Schematic of alleles used in panels F-J.  F) Overall survival of KMC 
(N=19, from Fig. 2C) and KMC-Miz1fl/fl (N=12) mice.  *** denotes p<0.001; Mantel Cox Logrank test 
(panels F, J).  G)  Quantification of tumour infiltrating NK (NKp46+) and B (CD45R+) cells in KMC and 
KMC Miz1fl/fl pancreatic tumours. Mann-Whitney Test (panels G, I).  H) IHC detection of tumour 
infiltrating NK and B cells after 3 weeks of IFNAR-1 blockade in KMC-Miz1fl/fl PDAC.  Scale bars = 
100µm.  I)  Quantification of tumour infiltrating NK (NKp46+) and B (CD45R+) cells in untreated (N=11 
& 10, respectively; from panel G) versus IFNAR1 antibody treated (3 weeks treatment, N=5) KMC-
Miz1fl/fl PDAC.  J) Overall survival of KMC-Miz1fl/fl mice treated with (N=7) or without (N=12, from 
panel F) anti-IFNAR1 blocking antibody.  For all panels, *** denotes p<0.001, **denotes p<0.01, * 
denotes p<0.05, ns = not significant. 
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Figure 6: Cxcl13 mediates Interferon signalling to B and NK cells in PDAC 
 A) Normalised RNA-SEQ reads of Cxcl13 expression in KMC (N=6) and KMC Miz1fl/fl (N=5) pancreatic 
tumours.  B) In situ hybridization (ISH) analysis of Cxcl13-expressing cells in KMC and KMC-Miz1fl/fl 
tumours.  Lower panels show IHC for F4/80.  Scale bar = 100µm.  C) RT-PCR analysis of Cxcl13 gene 
expression in bone marrow-derived macrophages upon treatment (10ng/ml for 4hrs) with 
recombinant mouse IFNb1. Mean and SEM of technical replicates from 1 of 3 independent 
experiments. T test; nd = none detected.  D) RT-PCR analysis of Cxcl13 gene expression in bone 
marrow-derived macrophages after 24hrs treatment with conditioned media from MYC-depleted 
or control KMC tumour cells.  Macrophages were pre-treated (20µg/ml, overnight) with IFNAR1 
blocking antibody or isotype control, where indicated.  Mean and SEM of technical replicates from 
1 of 3 independent experiments.  ANOVA and Tukey post-hoc test; nd = none detected.  E) IHC 
detection of tumour infiltrating NK and B cells after 3 weeks blockade of Cxcl13 in KMC-Miz1fl/fl 
PDAC. Scale bars = 100µm.  F)  Quantification of tumour infiltrating NK (NKp46+) and B (CD45R+) 
cells in untreated (N=11 & 10, respectively, from Figure 5G) and anti-Cxcl13-treated (N=6) KMC-
Miz1fl/fl PDAC.  Mann Whitney test.  G) Overall survival of KMC-Miz1fl/fl mice treated with (N=6) or 
without (N=12, from Fig. 5F) anti-Cxcl13 blocking antibody for 3 weeks.  Mantel Cox logrank test (G, 
H).  H) Overall survival of KMC-Miz1fl/fl mice treated with (N=6) or without (N=12, from Fig. 5F) anti-
NK1.1 depleting antibody for 4 weeks.  I) FACS analysis of Zombie NIRTM labelling of target cells 
(KMC, Yac-1, Fibroblasts) co-cultured with IL-2 stimulated, NK cell enriched splenocytes for 4hrs. 
Mean and SEM of 3 independent experiments shown. 2-way ANOVA and Tukey’s multiple 
comparisons test.   J) Model showing the mechanism of MYC/Miz1-dependent immune evasion in 
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